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Abstract
Background
In primary care, multiple priorities and system pressures make closing the gap between evi-
dence and practice challenging. Most implementation studies focus on single conditions,
limiting generalisability. We compared an adaptable implementation package against an
implementation control and assessed effects on adherence to four different evidence-based
quality indicators.
Methods and findings
We undertook two parallel, pragmatic cluster-randomised trials using balanced incomplete
block designs in general practices in West Yorkshire, England. We used ‘opt-out’ recruit-
ment, and we randomly assigned practices that did not opt out to an implementation pack-
age targeting either diabetes control or risky prescribing (Trial 1); or blood pressure (BP)
control or anticoagulation in atrial fibrillation (AF) (Trial 2). Within trials, each arm acted as
the implementation control comparison for the other targeted indicator. For example, prac-
tices assigned to the diabetes control package acted as the comparison for practices
assigned to the risky prescribing package. The implementation package embedded behav-
iour change techniques within audit and feedback, educational outreach, and computerised
support, with content tailored to each indicator. Respective patient-level primary endpoints
at 11 months comprised the following: achievement of all recommended levels of haemoglo-
bin A1c (HbA1c), BP, and cholesterol; risky prescribing levels; achievement of recom-
mended BP; and anticoagulation prescribing. Between February and March 2015, we
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recruited 144 general practices collectively serving over 1 million patients. We stratified
computer-generated randomisation by area, list size, and pre-intervention outcome achieve-
ment. In April 2015, we randomised 80 practices to Trial 1 (40 per arm) and 64 to Trial 2 (32
per arm). Practices and trial personnel were not blind to allocation. Two practices were lost
to follow-up but provided some outcome data. We analysed the intention-to-treat (ITT) popu-
lation, adjusted for potential confounders at patient level (sex, age) and practice level (list
size, locality, pre-intervention achievement against primary outcomes, total quality scores,
and levels of patient co-morbidity), and analysed cost-effectiveness. The implementation
package reduced risky prescribing (odds ratio [OR] 0.82; 97.5% confidence interval [CI]
0.67–0.99, p = 0.017) with an incremental cost-effectiveness ratio of £1,359 per quality-
adjusted life year (QALY), but there was insufficient evidence of effect on other primary end-
points (diabetes control OR 1.03, 97.5% CI 0.89–1.18, p = 0.693; BP control OR 1.05,
97.5% CI 0.96–1.16, p = 0.215; anticoagulation prescribing OR 0.90, 97.5% CI 0.75–1.09, p
= 0.214). No statistically significant effects were observed in any secondary outcome except
for reduced co-prescription of aspirin and clopidogrel without gastro-protection in patients
aged 65 and over (adjusted OR 0.62; 97.5% CI 0.39–0.99; p = 0.021). Main study limitations
concern our inability to make any inferences about the relative effects of individual interven-
tion components, given the multifaceted nature of the implementation package, and that the
composite endpoint for diabetes control may have been too challenging to achieve.
Conclusions
In this study, we observed that a multifaceted implementation package was clinically and
cost-effective for targeting prescribing behaviours within the control of clinicians but not for
more complex behaviours that also required patient engagement.
Trial registration
The study is registered with the ISRCTN registry (ISRCTN91989345).
Author summary
Why was this study done?
• Commonly used interventions to implement evidence-based practice, e.g., audit and
feedback, educational outreach, and computerised prompts, generally have modest if
variable effects on clinical performance.
• The effects of such interventions may be enhanced by tailoring them to identified needs
and barriers.
• Trials of implementation interventions typically address single conditions; it is difficult
to judge whether an intervention that works for one condition will work for another.
An adaptable implementation package in primary care
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What did the researchers do and find?
• We conducted two parallel, pragmatic trials to evaluate an implementation package for
primary care that was adapted to overcome barriers for different clinical priorities.
• General practices were randomly assigned to receive an implementation package target-
ing diabetes control or risky prescribing (Trial 1); blood pressure control or anticoagula-
tion in atrial fibrillation (Trial 2). Respective primary endpoints assessed were as
follows: achievement of all recommended levels of haemoglobin A1c, BP, and choles-
terol; risky prescribing levels; achievement of recommended BP; and anticoagulation
prescribing.
• The implementation package produced a significant clinically and cost-effective reduc-
tion in one target only: risky prescribing.
What do these findings mean?
• In this study, we found that an adaptable implementation package was cost-effective for
targeting prescribing behaviours within the control of clinicians, but not for more com-
plex behaviours that also required patient engagement.
• Given known associations between risky prescribing combinations and increased mor-
bidity, mortality, and health service use, a scaled-up risky prescribing implementation
package could have an important population impact.
Introduction
Clinical research can only benefit patient and population health if findings are incorporated
into routine care. There are delays and inappropriate variations in uptake of effective treat-
ments and withdrawal of less effective or harmful treatments [1]. This translation gap is impor-
tant to policy makers, healthcare systems, and research funders because it limits the health,
social, and economic impacts of clinical research [2].
United Kingdom primary care presents particular implementation challenges: growing
demand, increasing complexity of care, and limited workforce capacity, against a background
of frequent organisational reconfigurations [3,4]. We identified 107 clinical guidelines pro-
duced by the National Institute for Health and Care Excellence (NICE) relevant to UK general
practice [5]. Many implementation studies focus on a single clinical condition or problem
(e.g., diabetes, antibiotic stewardship), limiting generalisability, as it is uncertain whether an
implementation strategy developed for one condition will work for another. It is impracticable
and inefficient to devise an implementation strategy for every new guideline. Furthermore, the
clinical significance of behaviours often targeted in implementation studies, such as receipt of
processes of care or investigations, is doubtful [6]. Implementation strategies are required,
capable of integration into primary care systems and adaptable to different clinical priorities.
We earlier derived evidence-based indicators that could be measured using routinely col-
lected data [5]. We found marked variations in indicator achievement and scope for improve-
ment in a sample of 89 general practices [7]. We subsequently focused our efforts on four ‘high
An adaptable implementation package in primary care
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impact’ indicators that would benefit population health if implemented more consistently:
achievement of recommended treatment targets for all of haemoglobin A1c (HbA1c), blood
pressure (BP), and cholesterol in type 2 diabetes [8]; avoidance of risky prescribing of nonste-
roidal anti-inflammatory drugs (NSAIDs) and anti-platelet drugs [9]; achievement of recom-
mended BP levels in patients at high risk of cardiovascular events [10]; and anticoagulant
prescribing for stroke prevention in atrial fibrillation (AF) [11]. We drew upon systematic
reviews of implementation strategies [6,12–14], theory-guided interviews with primary care
staff [15], and workshops with health professionals and patients to develop a multifaceted
implementation package [16]. We compared the effects of the adaptable implementation pack-
age against implementation control on adherence to four different evidence-based high impact
indicators.
Methods
Study design and participants
We conducted two parallel, cluster-randomised trials using balanced incomplete block designs.
In implementation trials, there may be positive attention or negative demotivation effects from
participant knowledge of allocation to an intervention or control group, respectively. Balanced
incomplete block designs aim to balance any such nonspecific effects across trial arms, as each
arm receives an intervention, thereby increasing confidence that any difference in outcomes is
attributable to the intervention [17]. The design is incomplete, as each arm receives only one of
the interventions. General practices providing National Health Service (NHS) care were the
unit of allocation, as the intervention was delivered at the practice level. We maximised prag-
matism in trial design and execution to ensure ‘real-world’ relevance [18].
Practices were recruited fromWest Yorkshire, England, which covers a diverse population
of 2.2 million residents, albeit with deprivation levels above the national average [19]. Around
300 general practices were then organised within 10 clinical commissioning groups (CCGs).
Eligible general practices used SystmOne, the computerised clinical system used by approxi-
mately two thirds of West Yorkshire practices (The Phoenix Partnership, http://www.tpp-uk.
com). We excluded 31 practices that had contributed to earlier intervention development
work. We invited practices via recorded post and email, with reminders at two weeks. The UK
National Research Ethics Service granted ethical approval (14/SC/1393). This permitted use of
an opt-out approach: all eligible practices were included, unless actively declined within four
weeks of invitation. The study protocol has previously been published [20]. The study is regis-
tered with the ISRCTN registry (ISRCTN91989345). This study is reported as per the CON-
SORT guideline for cluster-randomised trials (S1 CONSORT checklist).
Randomisation and masking
The trial statistician performed the two-stage randomisation using a bespoke computer-gen-
erated minimisation programme implemented in R, software version 2.15.2 (R Foundation
for Statistical Computing, Vienna, Austria) (incorporating a random element). First,
practices were stratified by CCG and list size, and randomised to Trial 1 (implementation
packages targeting either diabetes control or risky prescribing), Trial 2 (BP control or antic-
oagulation in AF), or no intervention (80:64:34). As recruitment exceeded expectations, we
included a ‘no intervention’ arm to allow us to evaluate any nonspecific effects of research
participation (this paper presents comparisons within Trials 1 and 2; analysis of the no inter-
vention group will be reported elsewhere). Secondly, within each trial we stratified practices
by CCG, list size, and pre-intervention adherence to the two relevant targeted indicators and
randomised them 1:1 to individual trial arms (Fig 1). Within each trial, we assumed that any
An adaptable implementation package in primary care
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Fig 1. Trial profile. aSafe haven practices are for those patients who have demonstrated violent tendencies, who have been removed
from usual general practice, or for ex-offenders. bThe flow diagram presents the whole randomisation process, but this paper reports the
planned comparisons within Trials 1 and 2. The no intervention arm is shaded to indicate that it was not included in the analyses
described here; analysis of this group will be reported elsewhere. cOne practice in the risky prescribing armmerged with a non-ASPIRE
practice in advance of the fourth feedback report. However, as they received the first three feedback reports, some outcome data are
available, and they are included in the final analyses. dOne practice in the BP control arm closed in advance of the third feedback report.
However, as they received the first two feedback reports, some outcome data are available and they are included in the final analyses. As
an example, for the diabetes control practices: there were 14,522 patients acting as the intervention group for the diabetes control
implementation package and 18,131 patients acting as the control group for the risky prescribing implementation package. A&F follow-
up: delivery of audit and feedback reports during the intervention period; AF, atrial fibrillation; BP, blood pressure; RP, risky
prescribing.
https://doi.org/10.1371/journal.pmed.1003045.g001
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clinical effects of either implementation package would be independent of one another; each
intervention arm therefore acted as the control arm for the other intervention arm in the
same trial. For example, practices assigned to the diabetes control package acted as the
implementation control comparison for practices assigned to the risky prescribing package.
Practices from one CCG (29 practices) involved in a concurrent initiative targeting one of
our study priorities, anticoagulation in AF, were excluded from Trial 2. Practices and trial
personnel were not blind to allocation.
General practice and trial personnel involved in intervention delivery and trial statisticians
responsible for analysis were, of necessity, aware of allocation assignment. Data collection for
all endpoints was masked to allocation.
Procedures
The implementation package (detailed elsewhere [16]) embedded behaviour change tech-
niques within typical primary care interventions: audit and feedback, educational outreach,
and computerised support. Implementation package content, specifically the clinical content
and embedded behaviour change techniques, was adapted for each of the four targeted indica-
tors and delivered to practices May 2015 to March 2016.
Audit and feedback aimed to give comparative feedback on achievement, inform and
prompt recall of clinical goals, highlight consequences of changing or not changing practice,
suggest strategies for change, and encourage goal setting and reflection on progress towards
goals. Quarterly electronic and paper practice–specific reports presented achievement ranked
by practice and compared over time for relevant trial indicators in graphical and numerical
forms, using remotely gathered, individualised practice data. Reports also contained brief, evi-
dence-based clinical messages; responses to common queries; and action-planning templates.
Practices received computerised search tools to identify relevant patients for review. We
encouraged practices to use the feedback reports as supporting materials for professional
appraisal and revalidation.
Educational outreach aimed to enhance feedback reports by facilitating individual and
group reflection, discussing barriers to action, sharing models of good practice, enhancing
motivation, and action planning. We trained pharmacists over two days to deliver 30-minute
sessions, designed to fit with existing practice meetings and offered to all staff involved in
patient and practice management. We identified a key clinical contact to support practice
engagement. We offered a second, follow-up session to review progress and refine action
plans, as well as two days of pharmacist support for patient identification and review.
Prompts and reminders reinforced clinical messages and indicator adherence. Comput-
erised prompts for risky prescribing were offered to practices and had to be accepted before
they became active on their system. If accepted, they were triggered during consultations
and repeat prescribing through an algorithm for patient age, diagnosis, drug, and duration.
A one-click justification (ignore, or add or stop medication) was required before users could
proceed. Other targeted indicators had existing prompts on practice computer systems, usu-
ally to support the Quality Outcomes Framework (QOF), a performance management sys-
tem whereby general practices are remunerated according to achievement of targets
reflecting quality of care [21]. We provided laminated reminders to convey key clinical
information (e.g., management pathways) for BP control, anticoagulation for AF, and risky
prescribing. We also developed checklists to facilitate shared decision-making with patients
for managing BP and diabetes, but we could not make them available in a satisfactory format
within the study time lines [16].
An adaptable implementation package in primary care
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We deliberately aligned intervention delivery with the QOF year to fit with existing practice
schedules. We assumed that any actions prompted by the implementation package would
occur within this period.
Outcomes
Anonymised patient-level outcome data were obtained remotely from general practices from
SystmOne. We planned to measure all outcomes at 12 months post-randomisation. However,
a one-month delay in randomisation effectively meant that we were only able to assess out-
comes at 11 rather than 12 months.
The primary outcomes for each intervention arm comprised the following:
Trial 1. • Proportion of patients with type 2 diabetes achieving all three treatment targets:
a. BP below 140/80 mmHg (or 130/80 mmHg if kidney, eye, or cerebrovascular damage);
b. HbA1c value below or equal to 59 mmol/mol;
c. cholesterol level below or equal to 5.0 mmol/L.
• Proportion of patients meeting at least one of nine indicators of high-risk NSAID and anti-
platelet prescribing:
a. prescription of a traditional oral NSAID or low-dose aspirin in patients with a history of
peptic ulceration without co-prescription of gastro-protection;
b. traditional oral NSAID in patients aged 75 years or over without co-prescription of gas-
tro-protection;
c. traditional oral NSAID and aspirin in patients aged 65 years or over without co-prescrip-
tion of gastro-protection;
d. aspirin and clopidogrel in patients aged 65 years or over without co-prescription of gas-
tro-protection;
e. warfarin and traditional oral NSAID;
f. warfarin and low-dose aspirin or clopidogrel without co-prescription of gastro-
protection;
g. oral NSAID in patients with heart failure;
h. oral NSAID in patients prescribed both a diuretic and an angiotensin-converting-
enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB);
i. oral NSAID in patients with chronic kidney disease (CKD).
Trial 2. • Proportion of patients achieving the lowest appropriate BP target:
a. under 140/90 mmHg if aged under 80 years with hypertension, coronary heart disease,
peripheral arterial disease, a history of stroke or transient ischemic attack, or a 10-year
cardiovascular disease risk of 20% or higher;
b. under 150/90 mmHg if aged 80 years and over with hypertension;
c. under 140/80 mmHg if aged under 80 years with diabetes, under 130/80 mmHg if com-
plications of diabetes or aged under 80 years with CKD and proteinuria.
An adaptable implementation package in primary care
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• Combined proportion of men with AF and a congestive heart failure, hypertension, age�75,
diabetes, stroke, vascular disease, age between 65 and 74, and female sex (CHA2DS2-VASc)
score of 1 and women with a CHA2DS2-VASc score of 2 or above prescribed anticoagulation
therapy.
Secondary outcomes (S1–S4 Tables) included individual indicators contributing to composite
primary outcomes, processes of care, and continuous intermediate clinical outcomes (last
recorded BP, HbA1c, cholesterol). We assessed QOF indicators relevant to implementation
packages (diabetes control, BP control, and anticoagulation for AF) to examine any effects
on existing routine indicators. We assessed QOF indicators not directly targeted by the imple-
mentation packages to assess any unintended wider impacts. These included coronary heart
disease and asthma as example long-term physical conditions, mental health (long-term non-
physical condition), and smoking (health promotion).
We obtained practice characteristic data from publicly available sources (Health Education
England, Health and Social Care Information Centre): practice list size (number of registered
patients); number of general practitioner (GP) partners and salaried GPs; practice training
status; practice level Index of Multiple Deprivation (IMD); ethnic profile of practice register;
achievement of QOF indicators (2014–2015); patient satisfaction (proportion who would
recommend the practice to others); patient-rated practice accessibility (proportion able to
speak with GP or nurse within 48 hours of approach); and practice prescribing costs. Patient
characteristics (age, sex, comorbidity [number of QOF disease registers on which the patient
appeared]) and outcome data were extracted from SystmOne by the local primary care
commissioning support unit.
We monitored intervention delivery and fidelity via standardised report forms completed
by outreach facilitators following each visit. We recorded reasons for declining visits. We mon-
itored which practices accepted the invitation to join indicator-specific SystmOne organisa-
tional groups to access patient searches and any related computerised prompts.
Sample size
Median effect sizes on processes and outcomes of care for a range of guideline implementation
studies are around 4%–9% [6]. Given our enhanced interventions and targeting of indicators
with scope for improvement [12], we judged an absolute difference of 15% for outcomes
related to diabetes, BP control, and anticoagulation for AF as realistic and clinically relevant.
Baseline achievement rates in risky prescribing were considerably higher and, considering a
potential ceiling effect, a 5% decrease was realistic and clinically relevant.
We aimed to recruit 144 practices: 80 in Trial 1 (diabetes and risky prescribing) and 64 in
Trial 2 (BP control and AF), giving 90% power at 2.5% significance (adjusting for two compar-
isons per trial) to detect the specified effect sizes, allowing for 10% attrition. The mean cluster
size (number of patients per practice by indicator), coefficient of variation, intra-cluster corre-
lation coefficient (ICC), and control group achievement rates were estimated from previously
collected data [7,20] (S5 Table).
Statistical analysis
Analyses, conducted in SAS software version 9.4 (SAS Institute Inc., Cary, NC) according to
the prespecified statistical analysis plan (S1 statistical analysis plan), were based on intention-
to-treat (ITT), with two-sided significance testing at the 2.5% level to preserve an overall 5%
Type I error rate per trial. We analysed primary outcomes using two-level binary logistic
regression models, with patients (level 1) nested within randomised practices (level 2). We
An adaptable implementation package in primary care
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analysed binary secondary outcomes for individual indicators within the composite primary
outcomes, and recorded processes of care using similar multilevel logistic models. We analysed
continuous intermediate clinical outcomes using two-level linear models. All analyses adjusted
for patient-level (sex, age) and practice-level covariates (baseline practice list size, CCG, pre-
intervention achievement against primary outcomes, total QOF score 2014–2015 [covering
clinical and management domains], proportion of patients with 0–3 comorbidities). Sensitivity
analyses were conducted when model assumptions were violated. Data completeness for
these analyses depended on the completeness of SystmOnemedical records and could not
be assessed within the trial data set. Missing data in a patient’s record could have led to their
incorrect inclusion or exclusion from the denominator of a particular quality indicator or
resulted in the patient being incorrectly classified as achieving that indicator. For the primary
and secondary analyses, we assumed that data were missing at random. Imputation was not
performed for any outcome variables. Complete case analyses were performed for the continu-
ous clinical outcomes. No adjustment for multiple comparisons was made in the secondary
endpoint analyses.
Cost-effectiveness
We conducted economic evaluations of three implementation packages using a decision-
analytic modelling approach. Given resource constraints, we were unable to evaluate the
anticoagulation for AF package. Implementation package costs included researcher and
healthcare professional time and materials in delivery and resulting from change in practice.
Trial estimates of effectiveness were inputted into decision models, with the main output
being cost (UK £, 2017 prices) per incremental quality-adjusted life year (QALY) over a life-
time horizon from the perspective of the UK health and social care provider. Where possible
we used models, parameters, and assumptions that had informed the original NICE guid-
ance. For diabetes control, we used the UK Prospective Diabetes Study Outcomes Model
(UKPDS-OM) version 2 [22]. For BP control, we recreated and adapted the model used to
inform NICE guidance [23], identifying additional parameters through targeted searches
and risk engines such as QRISK. We based the risky prescribing model on a previous model
of NSAID prescribing used in a NICE osteoarthritis guideline (CG177). We adapted this
model and populated it using results reported for three of the most commonly prescribed
NSAIDs in the UK (diclofenac, naproxen, and ibuprofen) and aspirin. We created an
additional model based on that used to inform the NICE Acute Kidney Injury guideline
(CG169), covering NSAID prescribing in patients with CKD. Individual indicators were
evaluated and their cost-effectiveness aggregated within each implementation package. We
conducted a series of deterministic sensitivity analyses and a probabilistic sensitivity analy-
sis. We used a willingness to pay threshold of £20,000 per QALY gained to indicate cost-
effectiveness. We applied a 3.5% discount rate to costs and benefits post one year.
Results
We assessed 278 practices for eligibility in January 2015, excluding 35 because of closure or
earlier participation in the programme (Fig 1). We invited 243 (87%) practices to participate
in February 2015; 56 (23%) opted out, largely because of workload pressures, and nine were
excluded for other reasons.
In April 2015, we randomised 178 (73%) practices to Trial 1 (80 practices), Trial 2 (64 prac-
tices), or no intervention (34 practices). Analyses of the no intervention arm will be reported
elsewhere. Within each trial, practices were randomised 1:1 to intervention arms.
An adaptable implementation package in primary care
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Baseline characteristics for general practices and patients were well balanced by trial and
intervention (Tables 1 and 2). The mean practice IMD was 30.22 (SD 13.86) within the top
quarter of UK social deprivation [24].
No practices actively withdrew from the trial. One practice closed (BP intervention arm),
another merged (risky prescribing) with a non-trial practice during the intervention period,
and two trial practices merged (diabetes and risky prescribing). As outcome data for these
practices were available up to the times of the second, third, and fourth feedback reports,
respectively, all were included in the analysis using their most recent data.
Between May 2015 and April 2016, all intervention practices received feedback reports as
intended, including an end-of-study report (S6 Table summarises intervention delivery). Edu-
cational outreach visits were delivered to 67 (47%) of 144 practices; 52 (68%) of the 77 practices
declining visits gave no reason. Sixteen practices (24% of those receiving educational outreach
visits) utilised additional pharmacist support. One hundred twenty-six (88%) practices joined
the organisational groups, allowing them to access searches and computerised prompts (risky
prescribing practices only). Second educational visits were delivered to eight (6%) practices.
Table 1. General practice characteristics at baseline by trial arm.
Practice characteristics Trial intervention Total (n = 144)a
Diabetes control (n = 40) Risky prescribing (n = 40) BP control (n = 32) Anticoagulation in AF (n = 32)
List size
Mean (SD) 7,084.4 (3,786.5) 7,175.8 (3,857.0) 7,538.9 (4,932.9) 7,421.3 (4,171.2) 7,285.6 (4,128.9)
Overall QOF score 2014/2015b
Mean (SD) 535.4 (29.9) 531.1 (35.8) 527.2 (27.0) 533.0 (21.7) 531.9 (29.4)
Pre-intervention achievement (%) on primary outcome
Diabetes control
Mean (SD) 32.9 (6.9) 34.3 (7.7) 32.5 (7.1) 33.4 (5.5) 33.3 (6.9)
Risky prescribing
Mean (SD) 7.9 (5.1) 7.9 (3.6) 7.3 (3.6) 7.9 (2.5) 7.8 (3.9)
BP control
Mean (SD) 66.5 (6.4) 66.4 (7.0) 65.9 (7.5) 65.3 (6.2) 66.1 (6.8)
Anticoagulation in AF
Mean (SD) 66.5 (14.4) 67.3 (8.4) 66.5 (10.8) 66.3 (8.3) 66.7 (10.8)
Deprivation score (IMD 2015)
Mean (SD) 30.3(13.0) 32.4 (13.7) 28.3 (14.6) 29.3 (14.7) 30.2 (13.9)
Number of GPs (FTE)
Mean (SD) 4.0 (3.0) 4.1 (2.6) 4.2 (3.1) 4.0 (2.8) 4.1 (2.8)
Number of GP partners (FTE)
Mean (SD) 3.3 (2.6) 3.5 (2.4) 3.6 (2.8) 3.4 (2.5) 3.4 (2.5)
Percentage of patients who would recommend practice to others
Mean (SD) 75.4 (14.5) 73.9 (14.0) 74.7 (13.9) 76.0 (13.5) 75.0 (13.9)
Percentage of patients who saw/spoke to nurse or GP within 48 hours of approach
Mean (SD) 51.7 (17.3) 50.7 (15.6) 50.8 (12.9) 52.7 (16.1) 51.5 (15.5)
Teaching practice?
Yes 14 (35%) 15 (38%) 13 (41%) 15 (47%) 57 (40%)
No 26 (65%) 25 (63%) 19 (59%) 17 (53%) 87 (60%)
aThe practices randomised to the no intervention arm are not included here.
bThere was one practice with a missing value for overall QOF score in Trial 2. The 2014/2015 QOF measured achievement against 81 indicators; practices scored points
on the basis of achievement against each indicator, up to a maximum of 559.
Abbreviations: AF, atrial fibrillation; BP, blood pressure; FTE, full-time equivalent; GP, general practitioner; IMD, Index of Multiple Deprivation; QOF, Quality and
Outcomes Framework, total score 2014/2015
https://doi.org/10.1371/journal.pmed.1003045.t001
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Primary analyses demonstrated varying results across the implementation packages at 11
months post-randomisation (Table 3).
The diabetes implementation package had no observed effect on diabetes treatment targets.
Achievement was 24.2% in intervention practices; 23.7% in control practices (adjusted odds
ratio [OR] 1.03; 97.5% confidence interval [CI] 0.89–1.18; p = 0.693; ICC = 0.015).
Table 2. Patient characteristics at baseline by trial arm (all patients from all practices in each intervention arm).
Patient
characteristics
Trial intervention Total
(n = 1,067,402)aDiabetes control
(n = 288,130)
Risky prescribing
(n = 290,407)
BP control
(n = 249,571)
Anticoagulation in AF
(n = 239,294)
Age (years)
Mean (SD) 38.0 (22.9) 37.6 (23.1) 39.4 (23.2) 39.0 (23.2) 38.4 (23.1)
Sexb
Female 141,328 (49%) 144,426 (50%) 124,824 (50%) 120,289 (50%) 530,867 (50%)
Comorbidityc
0–3 276,280 (96%) 277,184 (95%) 239,455 (96%) 229,329 (96%) 1,022,248 (96%)
4+ 11,850 (4%) 13,223 (5%) 10,116 (4%) 9,965 (4%) 45,154 (4%)
aThe practices randomised to the no intervention arm are not included here.
bEach arm included<0.001% of patients defined as indeterminate or unknown.
cMeasured as the number of QOF registers on which a patient appears.
Abbreviations: AF, atrial fibrillation; BP, blood pressure; QOF, Quality Outcomes Framework
https://doi.org/10.1371/journal.pmed.1003045.t002
Table 3. Primary outcome achievement: Baseline rates, outcome rates, and ORs adjusted for baseline achievement and covariates.
Primary outcomes Baseline achievementa
(%)
Unadjusted model estimates Adjusted model estimatesc
Outcome achievementb
(%)
OR (97.5% CI) p-value Outcome achievementb
(%)
OR (97.5% CI) p-value ICC
Trial 1: Diabetes control
Intervention 33.7 24.3 1.016 (0.86–
1.20)
0.837 24.2 1.025 (0.89–
1.18)
0.693 0.015
Control (risky prescribing) 34.4 24.0 23.7
Trial 1: Risky prescribing
Intervention 7.2 5.2 0.783 (0.59–
1.04)
0.052 4.9 0.815 (0.67–
0.99)
0.017 0.022
Control (diabetes control) 7.4 6.5 6.0
Trial 2: BP control
Intervention 66.7 52.9 1.067 (0.94–
1.22)
0.266 53.6 1.053 (0.96–
1.16)
0.215 0.006
Control (anticoagulation in
AF)
65.5 51.2 52.3
Trial 2: Anticoagulation in
AF
Intervention 66.4 72.8 0.866 (0.68–
1.10)
0.175 73.2 0.902 (0.75–
1.09)
0.214 0.009
Control (BP control) 67.5 75.5 75.2
aCalculation of achievement for diabetes control and BP control at baseline uses any BP measurement taken in the previous 12 months.
bCalculation of achievement for diabetes control and BP control at outcome uses the most recent BP measurement taken.
cVariables controlled for in the adjusted analyses were as follows: patient-level sex and age, and practice-level baseline list size, CCG, pre-intervention achievement
against primary outcomes, total QOF score 2014–2015, and proportion of patients with 0–3 comorbidities.
Abbreviations: AF, atrial fibrillation; BP, blood pressure; CCG, clinical commissioning group; CI, confidence interval; ICC, intra-cluster correlation coefficient; OR,
odds ratio; QOF, Quality Outcomes Framework
https://doi.org/10.1371/journal.pmed.1003045.t003
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The risky prescribing implementation package reduced high-risk NSAID and anti-platelet
prescribing. In intervention practices, 4.9% of patients had a record of risky prescribing; 6.0%
in control practices (adjusted OR 0.82; 97.5% CI 0.67–0.99; p = 0.017; ICC = 0.022).
The BP implementation package had no observed effect on BP control. Achievement was
53.6% in intervention practices; 52.3% in control practices (adjusted OR 1.05, 97.5% CI 0.96–
1.16; p = 0.215; ICC = 0.006).
The AF implementation package had no observed effect on anticoagulant prescribing.
Achievement was 73.2% in intervention practices; 75.2% in control practices (adjusted OR
0.90; 97.5% CI 0.75–1.09; p = 0.214, ICC = 0.009).
There was little evidence of any intervention effects for any secondary outcome (S3–S6
Tables) except the risky prescribing implementation package, which showed some evidence of
improvement against an individual indicator: patients aged 65 years or over prescribed aspirin
and clopidogrel without co-prescription of gastro-protection. Adjusted prescribing levels were
25.3% in intervention practices, compared to 35.2% in control practices (adjusted OR 0.62;
97.5% CI 0.39–0.99; p = 0.021). The conclusions for total serum cholesterol and HbA1c were
robust to log transformation of the outcomes in a sensitivity analysis conducted following
model diagnostic checks. We observed no intervention effects on any QOF indicators, includ-
ing those not targeted by the implementation packages.
In estimating cost-effectiveness, we assumed equal costs for all four implementation pack-
ages. We conservatively doubled the cost per package. The total cost of package delivery was
£175,592, and cost per practice was £2,439 (£175,592/144�2). Costs per patient (not only those
eligible for indicator criteria) for an average practice list size of 7,130 were negligible (£0.28).
No interventions were cost-saving. The risky prescribing package is highly likely to be cost-
effective with an ICER of £1,359 and 79% chance of cost-effectiveness (Table 4), with results
largely driven by two indicators. While the deterministic ICER for the BP package indicates
cost-effectiveness, this is highly uncertain, with the probabilistic results indicating only a 52%
chance of cost-effectiveness. We have not presented model results for the diabetes package as
incremental costs and benefits were negligible, making model results unreliable. Results were
robust to deterministic sensitivity analyses when, for example, we increased and reduced inter-
vention costs. S1–S4 Figs present cost-effectiveness planes and acceptability curves for the
risky prescribing and BP control implementation packages.
Discussion
Our pragmatic, randomised trials found that an adaptable, multifaceted implementation pack-
age improved clinical care for only one of four high-impact indicators in general practices
serving relatively socially deprived populations. The odds of risky prescribing for a patient in
Table 4. Cost-effectiveness analysis: Mean probability sensitivity analysis outcomes at the practice level for the
primary risky prescribing and BP control outcomes.
Probability sensitivity analysis outcomes Risky prescribing BP control
Mean incremental QALY 0.90 13.00
Mean incremental cost £1,225 £42,192
ICER £1,359 £3,246
Incremental Net Monetary Benefit� £16,810 £217,730
Probability cost-effective 0.79 0.52
�Assumes willingness to pay threshold of £20,000.
Abbreviations: BP, blood pressure; ICER Incremental cost-effectiveness ratio; QALY, quality-adjusted life year
https://doi.org/10.1371/journal.pmed.1003045.t004
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an intervention practice were 18.5% lower than for a patient with the same characteristics in a
control practice, which could ultimately be associated with changes in mortality, morbidity,
and health service use, depending on generalisability to the general population. There was
insufficient evidence of an effect upon diabetes control, BP control, and anticoagulation for
AF. Our findings suggest that the design and delivery of implementation strategies need to
account for differences in the nature of targeted clinical behaviours and go further than the
kinds of adaptations in content that we applied.
Commonly used interventions to implement evidence-based practice, such as audit and
feedback, educational outreach, and computerised prompts generally have modest if variable
effects on clinical performance [12–14]. Tailoring such interventions to identified needs and
barriers offers a means to enhance their effects, but how best to do this and improve patient
outcomes remains uncertain [25].
Our findings confirm the effectiveness, generalisability, and value of interventions incorpo-
rating audit and feedback to improve prescribing safety in UK primary care [26–28]. The PIN-
CER trial compared one-off feedback with pharmacist outreach visits to one-off feedback
alone, whilst the D-QIP study provided financial incentives in addition to weekly feedback.
Given our pragmatic approach to practice recruitment, our intervention and findings compare
most closely to those of the EFIPPS trial, which found that quarterly feedback, with or without
embedded behaviour change techniques, reduced risky prescribing by a similar magnitude
[28]. Our modelling also indicated relative cost-effectiveness, mainly driven by improved levels
of gastro-protection. It is noteworthy that the cost of the risky prescribing package was only
£0.28 per patient.
We found no benefit of the implementation package on the management and outcomes of
our targeted long-term conditions. Systematic review evidence suggests that interventions
targeting systems of patient management along with patient-mediated interventions (which
we did not include) are likely to be important components of strategies in this context [29].
The balanced incomplete block designs permitted comparison of intervention effects while
mitigating any potential nonspecific performance effects of trial participation [30]. Our trials
were pragmatic in three ways. Opt-out recruitment ensured that participating practices were
generally representative of the wider population [19]. Data collection was minimally intrusive.
For intervention delivery, all practices received but were not obliged to act on feedback
reports, whilst outreach visits were optional. Hence, the implementation packages were tested
under real-world conditions, increasing confidence in wider applicability to routine general
practice settings. We further demonstrated no adverse impacts on incentivised indicators of
care not targeted by the implementation package.
Our evaluation had five main limitations. First, the use of routinely collected data may have
compromised the precision of trial outcomes and hence ability to demonstrate effects. How-
ever, we extracted structured data that are reasonably reliably coded in general practice, partly
incentivised by QOF. Second, given the multifaceted nature of the implementation package,
we cannot make any inferences about the relative effects of individual intervention compo-
nents. Third, educational outreach visits were delivered by facilitators not allocated to specific
trial arms, thereby risking contamination between arms. We had instructed facilitators to
focus only on delivering the implementation package to which each practice was assigned.
Fourth, an 11-month follow-up period may have been too short to detect changes in patient
outcomes, such as those related to diabetes or BP control, especially if a number of general
practices only received educational outreach visits later in this period. This explanation is
unlikely, as other trials have demonstrated changed clinical outcomes within similar durations
of follow-up [29]; we also did not detect any improvements in processes of care for diabetes
and BP control, respectively. Fifth, our composite endpoint for diabetes control requiring
An adaptable implementation package in primary care
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003045 February 28, 2020 13 / 20
achievement of all HbA1c, BP, and cholesterol treatment goals may have been too demanding.
Our clinical and patient advisors had considered this endpoint fair, if challenging.
Our work highlights three methodological issues. First, the implementation package effect
on risky prescribing was modest but important at a population level. Foregoing a randomised
design, as has been suggested for quality improvement research [31], would have reduced
confidence in the validity of our findings and risked false positive conclusions. For example,
the trial design accounted for temporal changes, including improvements in risky prescribing
and anticoagulation achievement and declines in BP and diabetes achievement (Table 3),
which would otherwise be difficult to interpret. Second, whilst we see the pragmatic design as
a strength, a more explanatory approach could have made full engagement with our imple-
mentation package a condition of trial participation. Such mandating is seldom possible or
even desirable in quality improvement programmes dependent upon professional engage-
ment, particularly if they encourage ‘gaming’ behaviours to achieve goals whilst circumventing
real action. Similarly, our opt-out approach to recruitment may have reduced self-selection of
more enthusiastic practices, as well as administrative burden. Those responsible for leading
quality improvement initiatives often specifically wish to include less enthusiastic or poorer
performing practices. Third, a critical challenge prior to pragmatic evaluations is to develop
interventions that are sufficiently durable to withstand the relatively hard-pressed and evolving
environments of clinical practice. Whilst we followed the UKMedical Research Council
framework for the development and evaluation of complex interventions, practice engagement
with our implementation package was highly variable [32]. We would now recommend more
intensive field work involving iterative cycles of testing and refining interventions prior to scal-
ing up for definitive evaluation.
We had set out to develop an implementation package that could be adapted for different
clinical priorities in primary care. We offer four interrelated explanations for the observed
differences in intervention effects. First, the targeted clinical behaviour(s) and associated
endpoints varied according to the extent of control held over them by clinical staff. Clinicians
could make relatively straightforward changes to reduce risky prescribing, such as adding
gastro-protection for prescribed aspirin, with limited input from patients. The observed signif-
icant difference in achievement of the associated secondary outcome on gastro-protection
provides evidence to support such a mechanism (although we would still advise cautious inter-
pretation, given that these analyses were not formally adjusted as we tested across multiple
secondary endpoints). In contrast, improving BP control can require at least two consultations
and changes in patient behaviour, as well as finding a pharmacological agent that is acceptable
to and effective for an individual patient. This is consistent with evidence that adherence to
clinical recommendations that are more complex or disruptive to routine practice is lower
compared with simpler recommendations [33]. Interventions involving audit and feedback
have also been shown to reduce other discouraged prescribing behaviours, namely of antibiot-
ics [34], and offer a means to address urgent priorities such as rising opioid prescribing [35].
Second, the risky prescribing package included an automated computerised prompt requiring
a one-step justification for continued prescribing. Such prompts are generally effective
in changing prescribing behaviour [14]. However, a recent UK trial found that on-screen
reminders did not improve adherence to the other prescribing behaviour we targeted, anticoa-
gulation prescribing for AF [36]. With the benefit of hindsight, this is unsurprising. Qualitative
work we undertook before the trials revealed that anticoagulation prescribing comprises a
series of deceptively complex considerations and behaviours, which include balancing benefits
and risks with patients [15]. Clinicians sometimes lacked confidence in starting treatment,
given that they encountered it relatively infrequently in routine practice and felt frustrated by
complicated guidance that made treatment difficult to explain to patients. Third, the number
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of patients requiring action to achieve indicators varied by trial arm, with far more in the dia-
betes and BP control arms relative to risky prescribing and anticoagulation for AF (see S5
Table). Hence, the larger numbers of patients requiring action may have undermined clini-
cians’ perceived feasibility and motivation. Moreover, making changes for even a small num-
ber of patients within the risky prescribing indicator set would have had a comparatively larger
effect upon achievement relative to other indicators. Fourth, the indicators for three targeted
long-term conditions were incentivised in the QOF. As well as aligning the implementation
package with existing quality improvement schemes, our intention had been to encourage
practices to move beyond the QOF by adopting more challenging, evidence-based goals.
Within the present constraints of UK primary care, it was hard for practices to take on addi-
tional, unrewarded work. Clinicians may, nevertheless, have been motivated to address risky
prescribing because it concerned patient safety.
In conclusion, an adaptable implementation package improved prescribing safety in general
practice. However, we observed no benefits of the package within the context of an existing
financial incentive system targeting similar aspects of care for three long-term conditions.
Improving patient outcomes for long-term conditions requiring relatively complex manage-
ment may require systemised approaches that target patient as well as professional behaviour.
Supporting information
S1 Table. Secondary outcomes from Trial 1: Achievement of individual indicators that
contributed to composite outcomes; processes of care; and continuous intermediate clini-
cal outcomes. All adjusted for covariates and baseline achievement of primary outcomes.
Table presents mean percentage achievement, unless otherwise stated. Variables controlled
for in the adjusted analyses were as follows: patient-level sex and age, and practice-level base-
line list size, CCG, pre-intervention achievement against primary outcomes, total QOF score
2014–2015, and proportion of patients with 0–3 comorbidities. ACE-I, angiotensin-convert-
ing-enzyme inhibitor; ACR: albumin:creatinine ratio; ARB, angiotensin receptor blocker;
BMI, body mass index; BP, blood pressure; CCG, clinical commissioning group; CI, confi-
dence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
HbA1c, haemoglobin A1c; NSAID, non-steroidal anti-inflammatory drug; PCR, protein:creat-
inine ratio; QOF, Quality Outcomes Framework.
(DOCX)
S2 Table. Secondary outcomes from Trial 1: Achievement of QOF indicators relating to
the implementation packages; and non-trial related QOF indicators. All adjusted for
covariates and baseline achievement of primary outcomes. Note: Formal statistical testing
was inappropriate due to violation of the modelling assumptions for the following trial-related
indicators: DM006, DM014, DM018; and the following non-trial related indicators: CHD005,
CHD007, MH002, MH003, SMOK004, and SMOK005. Summary statistics only are presented
for these indicators. †The HbA1c and total serum cholesterol continuous intermediate clinical
outcomes were analysed using a log transformation in order to satisfy the modelling assump-
tions. The predicted means presented are on the untransformed (original) scale, but the esti-
mated intervention effect (and 97.5% CI) are on the log scale. �If urine albumin:creatinine
ratio�3, or retinopathy, or record of cerebrovascular accident or transient ischemic attack.
Variables controlled for in the adjusted analyses were as follows: practice-level baseline list
size, CCG, pre-intervention achievement against primary outcomes, and total QOF score
2014–2015. ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor
blocker; CCG, clinical commissioning group; CHD, coronary heart disease; CI, confidence
interval; CKD, chronic kidney disease (stage 3–5); COPD, chronic obstructive pulmonary
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disease; HbA1c, haemoglobin A1c; IFCC, International Federation of Clinical Chemistry and
Laboratory Medicine; PAD, peripheral arterial disease; QOF, quality and outcomes frame-
work; RCP, Royal College of Physicians; TIA, transient ischemic attack.
(DOCX)
S3 Table. Secondary outcomes from Trial 2: Achievement of individual indicators that
contributed to composite outcomes; processes of care; and continuous intermediate clini-
cal outcomes. All adjusted for covariates and baseline achievement of primary outcomes.
Values are percentage achievement, unless otherwise stated. Variables controlled for in the
adjusted analyses were as follows: patient-level sex and age, and practice-level baseline list size,
CCG, pre-intervention achievement against primary outcomes, total QOF score 2014–2015,
and proportion of patients with 0–3 comorbidities. �If urine albumin:creatinine ratio�3, or
retinopathy, or record of cerebrovascular accident or transient ischemic attack. AF, atrial
fibrillation; BP, blood pressure; CCG, clinical commissioning group; CHA2DS2-VASc, conges-
tive heart failure, hypertension, age>75, diabetes, stroke, vascular disease, age between 65 and
74, and female sex; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney
disease; CVD, cardiovascular disease; HTN, hypertension; PAD, peripheral arterial disease;
QOF, Quality Outcomes Framework; TIA, transient ischemic attack.
(DOCX)
S4 Table. Secondary outcomes from Trial 2: Achievement of QOF indicators relating to
the implementation packages; and non-trial-related QOF indicators. All adjusted for
covariates and baseline achievement of primary outcomes. Note: Formal statistical testing
was inappropriate due to violation of the modelling assumptions for the following trial-related
indicators: AF006, AF007; and the following non-trial related indicators: CHD005, CHD007,
MH002, MH003, SMOK004, and SMOK005. Summary statistics only are presented for these
indicators. Variables controlled for in the adjusted analyses were as follows: practice-level base-
line list size, CCG, pre-intervention achievement against primary outcomes and total QOF
score 2014–2015. CCG, clinical commissioning group; CHA2DS2-VASc, congestive heart
failure, hypertension, age>75, diabetes, stroke, vascular disease, age between 65 and 74, and
female sex; CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney dis-
ease; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; QOF,
Quality and outcomes framework; RCP, Royal College of Physicians; TIA, transient ischemic
attack.
(DOCX)
S5 Table. Key sample size assumptions. Data from an earlier work package of the ASPIRE
programme were used to inform the trial sample size assumptions. Mean cluster size, cluster
size coefficient of variation, ICC, and mean achievement rates were calculated using real data
from practices within West Yorkshire for each primary outcome indicator. aMean achieve-
ment is the control arm achievement rate for each primary outcome indicator estimated
using data available from the earlier work package. ICC, intra-cluster correlation coefficient.
(DOCX)
S6 Table. Intervention delivery across trial practices. aOne practice in the risky prescribing
armmerged with a non-ASPIRE practice in advance of the final feedback report. bOne practice
in the BP arm closed in advance of the third feedback report. cOnly practices receiving an ini-
tial outreach visit were offered additional support; these practices are used as the denominator
in the percentages presented. dThese granted access to the computerised searches (all arms)
and prompts (risky prescribing only). BP, blood pressure.
(DOCX)
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S1 Fig. Scatterplot of simulated incremental cost and QALY for the composite indicator of
risky prescribing. ICER, incremental cost-effectiveness ratio; PSA, probability sensitivity anal-
ysis; QALY, quality-adjusted life year.
(TIF)
S2 Fig. Cost-effectiveness acceptability curve for the composite indicator of risky prescrib-
ing.QALY, quality-adjusted life year; WTP, Willingness to Pay.
(TIF)
S3 Fig. Scatterplot of simulated incremental cost and QALY for the composite indicator of
BP control. BP, blood pressure; ICER, incremental cost-effectiveness ratio; PSA, probability
sensitivity analysis; QALY, quality-adjusted life year.
(TIF)
S4 Fig. Cost-effectiveness acceptability curve for the composite indicator of BP control.
BP, blood pressure; QALY, quality-adjusted life year; WTP, Willingness to Pay.
(TIF)
S1 CONSORT Checklist.
(DOCX)
S1 Statistical Analysis Plan.
(DOCX)
S1 Trial Protocol.
(DOC)
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